Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,536 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK. Patnaik A, et al. Among authors: wolf j. Clin Cancer Res. 2006 Dec 15;12(24):7406-13. doi: 10.1158/1078-0432.CCR-06-1886. Clin Cancer Res. 2006. PMID: 17189413 Clinical Trial.
Effects of smoking on the pharmacokinetics of erlotinib.
Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ. Hamilton M, et al. Among authors: wolf jl. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. doi: 10.1158/1078-0432.CCR-05-2235. Clin Cancer Res. 2006. PMID: 16609030 Clinical Trial.
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, Ling J, Kenkare-Mitra SR, Lum BL. Frohna P, et al. Among authors: wolf j. J Clin Pharmacol. 2006 Mar;46(3):282-90. doi: 10.1177/0091270005284193. J Clin Pharmacol. 2006. PMID: 16490804 Clinical Trial.
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
O'Reilly EM, Roach J, Miller P, Yu KH, Tjan C, Rosano M, Krause S, Avery W, Wolf J, Flaherty K, Nix D, Ryan DP. O'Reilly EM, et al. Among authors: wolf j. Oncologist. 2017 Dec;22(12):1429-e139. doi: 10.1634/theoncologist.2017-0472. Epub 2017 Nov 20. Oncologist. 2017. PMID: 29158367 Free PMC article. Clinical Trial.
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.
O'Reilly EM, Barone D, Mahalingam D, Bekaii-Saab T, Shao SH, Wolf J, Rosano M, Krause S, Richards DA, Yu KH, Roach JM, Flaherty KT, Ryan DP. O'Reilly EM, et al. Among authors: wolf j. Eur J Cancer. 2020 Jun;132:112-121. doi: 10.1016/j.ejca.2020.03.005. Epub 2020 Apr 28. Eur J Cancer. 2020. PMID: 32361265 Free PMC article. Clinical Trial.
4,536 results